Posted by Michael Wonder on 13 Sep 2023
Paladin Labs announced favourable CADTH recommendation for Xcopri (cenobamate tablets)
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
This recommendation follows Health Canada's approval of Xcopri on 12 June 2023.
